Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed chronic hepatitis B patients with hepatic impairment: final 2 year efficacy and safety results from a phase 2, open-label study

被引：0

作者：

Lim, Young-Suk ^{[1
]}

Lin, Chun-yen ^{[2
,3
]}

Heo, Jeong ^{[4
]}

Bae, Ho ^{[5
]}

Chuang, Wan-Long ^{[6
]}

Tsang, Tak Yin Owen ^{[7
]}

Fournier, Claire ^{[8
]}

Hui, Aric Josun ^{[9
]}

Huy Trinh ^{[10
]}

Tan, Susanna ^{[11
]}

Zhao, Yang ^{[11
]}

Flaherty, John F. ^{[11
]}

Suri, Vithika ^{[11
]}

Gaggar, Anuj ^{[11
]}

Brainard, Diana ^{[11
]}

Ryder, Stephen ^{[12
,13
]}

Janssen, Harry L. A. ^{[14
]}

机构：

[1] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[2] Chang Gung Univ, Taoyuan, Taiwan

[3] Chang Gung Mem Hosp, Taoyuan, Taiwan

[4] Pusan Natl Univ, Sch Med, Pusan, South Korea

[5] Asian Pacific Liver Ctr, Los Angeles, CA USA

[6] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan

[7] Chinese Univ Hong Kong, Hong Kong, Peoples R China

[8] CHUM, Serv Hepatol, Montreal, PQ, Canada

[9] Alice Ho Miu Ling Nethersole Hosp, Tai Po, Hong Kong, Peoples R China

[10] San Jose Gastroenterol, San Jose, CA USA

[11] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[12] Nottingham Univ Hosp NHS Trust, Biomed Res Ctr Gastrointestinal & Liver Disorders, Nottingham, England

[13] Univ Nottingham, Nottingham, England

[14] Erasmus MC, Rotterdam, Netherlands

来源：

JOURNAL OF HEPATOLOGY | 2021年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

PO-2338

引用

页码：S755 / S756

页数：2

共 50 条

[21] A Phase 3 Study Comparing Switching: Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) With Continued TDF Treatment in Virologically Suppressed Patients With Chronic Hepatitis B: Final Week 96 Results
Khalili, Mandana
Lampertico, Pietro
Bae, Ho S.
Ma, Xiaoli
Ramji, Alnoor
Fung, Scott
Ahn, Sang Hoon
Kao, Jia-Horng
Tam, Edward
Halton, Patricia
Yee, Leland
Flaherty, John
Gaggar, Anuj
Liu, Yang
Wu, George
Hann, Hie-Won
Agarwal, Kosh
Lim, Young-Suk
Buti, Maria
Chan, Henry
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S543 - S543
[22] A PHASE 3 STUDY COMPARING SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) WITH CONTINUED TDF TREATMENT IN VIROLOGICALLY-SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B (CHB): WEEK 48 EFFICACY AND SAFETY RESULTS
Chan, Henry Lik Yuen
Lampertico, Pietro
Buti, Maria
Fung, Scott
Ahn, Sang Hoon
Chuang, Wan-Long
Tak, Won Young
Ramji, Alnoor
Chen, Chi-Yi
Tam, Edward
Bae, Ho
Ma, Xiaoli
Flaherty, John
Gaggar, Anuj
Lau, Audrey
Feierbach, Becket
Wu, George
Suri, Vithika
Subramanian, Mani
Huy Trinh
Yoon, Seung-Kew
Agarwal, Kosh
Lim, Young-Suk
GUT, 2019, 68 : A142 - A143
[23] A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96
Brunetto, M.
Lim, Y. S.
Gane, E.
Seto, W. K.
Osipenko, M.
Ahn, S. H.
Janssen, H. L.
Shukla, A.
Chuang, W. L.
Trinh, H.
Celen, M. K.
Flaherty, J. F.
Lau, A. H.
Gaggar, A.
Suri, V.
Bhardwaj, N.
Kim, K.
Subramanian, G. M.
Pan, C.
Izumi, N.
Marcellin, P.
Chan, H.
Buti, M.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S25 - S26
[24] A PHASE 3 STUDY OF TENOFOVIR ALAFENAMIDE COMPARED WITH TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HBEAG-NEGATIVE, CHRONIC HEPATITIS B: WEEK 48 EFFICACY AND SAFETY RESULTS
Buti, M.
Gane, E.
Seto, W. K.
Chan, H. L. Y.
Chuang, W. -L.
Stepanova, T.
Hui, A. J.
Lim, Y. -S.
Mehta, R.
Janssen, H. L. A.
Acharya, S. K.
Flaherty, J. F.
Massetto, B.
Cathcart, A.
Dinh, P.
Subramanian, G. M.
McHutchison, J. G.
Pan, C.
Brunetto, M.
Izumi, N.
Marcellin, P.
JOURNAL OF HEPATOLOGY, 2016, 64 : S135 - S136
[25] Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use
Janssen, H.
Gane, E.
Seto, W-K
Caruntu, F. A.
Kim, H. J.
Abdurakhmanov, D.
Nishiguchi, S.
Horban, A.
Bae, H.
Mo, S.
Suri, V.
Gaggar, A.
Flaherty, J.
Kao, J-H
Brunetto, M.
Ferret, M. B.
JOURNAL OF VIRAL HEPATITIS, 2018, 25 : 27 - 27
[26] Safety and Efficacy at 1 Year after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use
Gane, Edward
Seto, Wai Kay
Janssen, Harry L. A.
Caruntu, Florin A.
Kim, Hyung Joon
Abdurakhmanov, Dzhamal
Nishiguchi, Shuhei
Horban, Andrzej
Bae, Ho
Flaherty, John F.
Gaggar, Anuj
Suri, Vithika
Oberle, Corinna
Mo, Shuyuan
Subramanian, G. Mani
Kao, Jia-Horng
Brunetto, Maurizia
Buti, Maria
SWISS MEDICAL WEEKLY, 2018, 148 : 26S - 26S
[27] Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece
Sinakos, Emmanouil
Kachru, Nandita
Tsoulas, Christos
Jeyakumar, Sushanth
Smith, Nathaniel J.
Yehoshua, Alon
Cholongitas, Evangelos
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2024, 13 (04) : e230090
[28] EFFECTIVENESS AND SAFETY OF SWITCHING TENOFOVIR DISOPROXIL FUMARATE AND ENTECAVIR TO TENOFOVIR ALAFENAMIDE FUMARATE ( TAF) IN VIROLOGICALLY SUPPRESSED CHRONIC HEPATITIS B VIRUSINFECTED PATIENTS WITH ONEMINUTE OSTEOPOROSIS RISK TEST
Li, Hui
Li, Chunmei
Wei, Jia
Liu, Yunhua
Gong, Ming
Zhang, Ruyi
Geng, Jiawei
Wang, Hongyan
Yu, Zhijian
Wang, Zi
Liu, Xiang
HEPATOLOGY, 2023, 78 : S513 - S513
[29] EFFICACY AND SAFETY RESULTS 48 WEEKS AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) VS CONTINUED TDF TREATMENT IN VIROLOGICALLY-SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B (CHB)
Lampertico, Pietro
Buti, Maria
Fung, Scott
Ahn, Sang Hoon
Chuang, Wan-Long
Tak, Won Young
Ramji, Alnoor
Chen, Chi-Yi
Tam, Edward
Bae, Ho
Ma, Xiaoli
Flaherty, John F.
Gaggar, Anuj
Lau, Audrey H.
Feierbach, Becket
Wu, George
Suri, Vithika
Subramanian, Mani
Trinh, Huy N.
Yoon, Seung-Kew
Agarwal, Kosh
Lim, Young-Suk
Chan, Henry L.
GASTROENTEROLOGY, 2019, 156 (06) : S1195 - S1195
[30] Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study
Lampertico, Pietro
Buti, Maria
Fung, Scott
Ahn, Sang Hoon
Chuang, Wan-Long
Tak, Won Young
Ramji, Alnoor
Chen, Chi-Yi
Tam, Edward
Bae, Ho
Ma, Xiaoli
Flaherty, John F.
Gaggar, Anuj
Lau, Audrey
Liu, Yang
Wu, George
Suri, Vithika
Tan, Susanna K.
Subramanian, G. Mani
Trinh, Huy
Yoon, Seung-Kew
Agarwal, Kosh
Lim, Young-Suk
Chan, Henry L. Y.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (05): : 441 - 453

← 1 2 3 4 5 →